Apo2L/TRAIL and its death and decoy receptors

被引：726

作者：

LeBlanc, HN ^{[1
]}

Ashkenazi, A ^{[1
]}

机构：

[1] Genentech Inc, Dept Mol Oncol, San Francisco, CA 94080 USA

来源：

CELL DEATH AND DIFFERENTIATION | 2003年 / 10卷 / 01期

关键词：

apoptosis; caspases; TNF superfamily; Bcl-2; bax;

D O I：

10.1038/sj.cdd.4401187

中图分类号：

Q5 [生物化学]; Q7 [分子生物学];

学科分类号：

071010 ; 081704 ;

摘要：

Apo2 ligand or tumour necrosis factor-related apoptosis-inducing ligand (Apo2L/TRAIL) is one of the several members of the tumour necrosis factor (TNF) gene superfamily that induce apoptosis through engagement of death receptors (DRs). Apo2L/TRAIL interacts with an unusually complex receptor system of two DRs and three decoys. This protein has garnered intense interest as a potential candidate for cancer therapy because as a trimer it selectively induces apoptosis in many transformed cells but not in normal cells. While much of the early characterisation of Apo2L/TRAIL and its receptors relied on overexpression studies, recent work using untransfected cells has clarified how endogenous proteins transmit apoptotic signals from this ligand. In this review, we focus on the apoptotic signalling pathways stimulated by Apo2L/TRAIL and summarise what is known about its physiological role.

引用

页码：66 / 75

页数：10

共 108 条

[1] Genomic organization and mutation analyses of the DR5/TRAIL receptor 2 gene in colorectal carcinomas [J].

Arai, T ;

Akiyama, Y ;

Okabe, S ;

Saito, K ;

Iwai, T ;

Yuasa, Y .

CANCER LETTERS, 1998, 133 (02) :197-204

[2] Apoptosis control by death and decoy receptors [J].

Ashkenazi, A ;

Dixit, VM .

CURRENT OPINION IN CELL BIOLOGY, 1999, 11 (02) :255-260

[3] Safety and antitumor activity of recombinant soluble Apo2 ligand [J].

Ashkenazi, A ;

Pai, RC ;

Fong, S ;

Leung, S ;

Lawrence, DA ;

Masters, SA ;

Blackie, C ;

Chang, L ;

McMurtrey, AE ;

Hebert, A ;

DeForge, L ;

Koumenis, IL ;

Lewis, D ;

Harris, L ;

Bussiere, J ;

Koeppen, H ;

Shahrokh, Z ;

Schwall, RH .

JOURNAL OF CLINICAL INVESTIGATION, 1999, 104 (02) :155-162

[4] TRAIL receptor-2 signals apoptosis through FADD and caspase-8 [J].

Bodmer, JL ;

Holler, N ;

Reynard, S ;

Vinciguerra, P ;

Schneider, P ;

Juo, P ;

Blenis, J ;

Tschopp, J .

NATURE CELL BIOLOGY, 2000, 2 (04) :241-243

[5] Cysteine 230 is essential for the structure and activity of the cytotoxic ligand TRAIL [J].

Bodmer, JL ;

Meier, P ;

Tschopp, J ;

Schneider, P .

JOURNAL OF BIOLOGICAL CHEMISTRY, 2000, 275 (27) :20632-20637

[6]

Bouillet P, 2002, J CELL SCI, V115, P1567

[7]

Burns TF, 2001, J BIOL CHEM, V276, P37879

[8] Death receptor 5, a new member of the TNFR family, and DR4 induce FADD-dependent apoptosis and activate the NF-κB pathway [J].

Chaudhary, PM ;

Eby, M ;

Jasmin, A ;

Bookwalter, A ;

Murray, J ;

Hood, L .

IMMUNITY, 1997, 7 (06) :821-830

[9] Apo2L/TRAIL and Bcl-2-related proteins regulate type I interferon-induced in multiple myeloma [J].

Chen, Q ;

Gong, B ;

Mahmoud-Ahmed, AS ;

Zhou, A ;

Hsi, ED ;

Hussein, M ;

Almasan, A .

BLOOD, 2001, 98 (07) :2183-2192

[10] Combined effect of tumor necrosis factor-related apoptosis-inducing ligand and ionizing radiation in breast cancer therapy [J].

Chinnaiyan, AM ;

Prasad, U ;

Shankar, S ;

Hamstra, DA ;

Shanaiah, M ;

Chenevert, TL ;

Ross, BD ;

Rehemtulla, A .

PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2000, 97 (04) :1754-1759

← 1 2 3 4 5 6 7 8 9 10 →